Editas Medicine

Editas Medicine
Name	Editas Medicine
Foundation	0 2013
Founders	Feng Zhang, George Church, J. Keith Joung, David R. Liu
Location	Cambridge, Massachusetts, United States
Industry	Biotechnology
Key people	Gilmore O'Neill (CEO)
Products	Genome editing therapies
Website	www.editasmedicine.com

Editas Medicine is a clinical-stage biotechnology company pioneering the development of transformative, precision genome editing medicines for people with serious diseases. Founded by leading scientists in the CRISPR field, the company leverages a suite of technologies, including its proprietary AsCas12a enzyme, to create potentially curative treatments. Its pipeline focuses on developing in vivo and ex vivo therapies for a range of genetic disorders, with lead programs targeting sickle cell disease and Leber congenital amaurosis.

History

The company was founded in 2013 by renowned researchers Feng Zhang of the Broad Institute, George Church of Harvard University, J. Keith Joung from Massachusetts General Hospital, and David R. Liu of the Broad Institute. It emerged from the intense early-stage research and patent landscape surrounding the CRISPR-Cas9 system. In 2015, it received a significant investment from Bill Gates and other high-profile investors, and completed an initial public offering on the NASDAQ in 2016. Early strategic alliances were formed with Juno Therapeutics, later acquired by Celgene, and Allergan to advance ocular disease programs. The company's research and development operations are headquartered in the biotechnology hub of Cambridge, Massachusetts.

Technology and platform

The core platform is built around advanced genome editing tools, primarily based on the CRISPR-Cas9 and CRISPR-Cas12a systems. A key differentiator is the company's engineered AsCas12a enzyme, which offers potential advantages in specificity and efficiency for certain therapeutic applications. The technology suite includes both homology-directed repair and non-homologous end joining editing strategies. The company also develops proprietary delivery technologies, including lipid nanoparticles and adeno-associated virus vectors, to enable precise in vivo editing. This integrated approach is designed to target the root cause of genetic diseases at the DNA level across multiple therapeutic areas.

Clinical programs and pipeline

The lead clinical program, EDIT-301, is an investigational ex vivo therapy for sickle cell disease and beta thalassemia that edits the BCL11A gene in a patient's own hematopoietic stem cells to induce fetal hemoglobin production. Another key program, EDIT-101, was an in vivo CRISPR therapy developed for Leber congenital amaurosis type 10, targeting the CEP290 gene; this program was discontinued after clinical results. The pipeline includes earlier-stage research programs in other genetic diseases, leveraging both in vivo and ex vivo approaches. The company's strategy focuses on advancing multiple candidates from research into Investigational New Drug application stages and beyond.

Collaborations and partnerships

The company has established several strategic alliances to advance its technology and pipeline. A major multi-year research collaboration with Bristol Myers Squibb focuses on developing targeted ex vivo cell therapies for cancer and autoimmune diseases. Previous significant partnerships included an agreement with Allergan (now part of AbbVie) for ocular diseases like Leber congenital amaurosis, and an early alliance with Juno Therapeutics for CAR-T cell therapies. The company also engages in foundational research collaborations with academic institutions such as the Broad Institute and Massachusetts General Hospital to explore new editing technologies and therapeutic targets.

Leadership and corporate affairs

The company is led by President and Chief Executive Officer Gilmore O'Neill, a physician-scientist with extensive experience in drug development. The executive team and board of directors include leaders with backgrounds in biotechnology, clinical development, and finance from organizations like Vertex Pharmaceuticals, Biogen, and Merck & Co.. Corporate operations and research facilities are based in Cambridge, Massachusetts. The company actively manages a complex intellectual property portfolio related to CRISPR technology, navigating the ongoing patent disputes between the Broad Institute and the University of California, Berkeley.

See also

* CRISPR * Intellia Therapeutics * CRISPR Therapeutics * Sangamo Therapeutics * Beam Therapeutics * Precision medicine * Gene therapy * Genetic disorder

Category:Biotechnology companies of the United States Category:Companies based in Cambridge, Massachusetts Category:Genome editing companies